43 North Announces Semi-Finalists (Spoiler: this one’s connected to UR technologies)

Recently, 113 semi-finalists were announced in the 2014 43 North $1 million business plan competition. Ten of those semi-finalists are from the Rochester area. Four of those are connected to University of Rochester technologies.

SmartDialysis (Rochester, NY) is trying to create a portable hemodialysis device to improve the lives of ESRD patients. The company has expressed interest in the possibility of licensing select technologies is interested in licensing two technologies from the laboratory of James McGrath, an Associate Professor in the Department of Biomedical Engineering.

Rochester Shines in First Round of 43 North Business Plan Competition

On 15 July 2014, nearly 7,000 applicants from 96 countries were winnowed down to 113 semi-finalists in the $1 Million 43 North Business Plan Competition. It is very exciting to see that ten of the semi-finalists are from the Greater Rochester Area! They are:

  1. Artwork Evolution
  2. Braverman Consulting
  3. Clerisy Corp
  4. Empire Genomics, LLC
  5. Energy Harvesters, LLC
  6. Health Care Originals
  7. Ovitz Corporation
  8. Raland Therapeutics, Inc.
  9. SmartDialysis
  10. TeraPore Technologies, Inc.

Congratulations! And Best Wishes going forward!

A New Look for Our Website

The UR Ventures web site underwent a minor update last week. We have simplified navigation within the site, hopefully making the things you’re looking for a little easier to find.

As always, we welcome your feedback. Send comments and suggestions to the e-mail link, below.

Rochester and Cornell Team Up for Upstate Health Sciences Symposium

2014-Upstate Health Symposium

Eighty faculty and students from the University of Rochester and Cornell converged in Ithaca on Tuesday, 6 May 2014 for the Upstate New York Health Sciences Symposium and Technology Showcase. Attendees heard presentations from Cancer Biology and Neurobiology researchers and later mingled among more than two dozen posters detailing cutting-edge research being conducted at the two universities.

Telephus Aims to Tame Biofilms in Implantable Devices

BIOWORLD TODAY, 21 April 2014

By Marie Powers, Staff Writer

In Greek mythology, Telephus was a son of Heracles who received a wound in battle that would not heal until he returned to the Greek warrior, Achilles, who had inflicted the injury. He was healed by the very spear that had pierced him.

Real life is decidedly more complicated, but the fable is an apt metaphor for Telephus Medical LLC, which is developing a first-in-class humanized monoclonal antibody to prevent Staphylococcus reinfection and osteomyelitis in patients following total hip or knee replacement surgery. The company’s technology is designed to prevent the early events that drive the formation of antibiotic-resistant biofilm infections on implanted medical devices, which today require additional, revision surgery.

<--more-->

Wegman Foundation Donates $17 Million for Children’s Hospital and Institute for Data Science

Today, University of Rochester President Joel Seligman announced two extraordinary gifts from The Wegman Family Charitable Foundation (WFCF): a $10 million lead gift to the University’s Institute for Data Science and a $7 million gift to support Golisano Children’s Hospital. Together with previous gifts to several programs across the University campuses, today’s announcement brings to $20 million the WFCF’s total contributions to the University’s comprehensive campaign. In recognition of this support for the Institute for Data Science, the Institute’s new landmark building will bear the Wegmans name.

<--more-->

Finding Points to Possible New Parkinson’s Therapy

A new study shows that, when properly manipulated, a population of support cells found in the brain called astrocytes could provide a new and promising approach to treat Parkinson’s disease.  These findings, which were made using an animal model of the disease, demonstrate that a single therapy could simultaneously repair the multiple types of neurological damage caused by Parkinson’s, providing an overall benefit that has not been achieved in other approaches.
Read More